Overview of Dolo - 650

Quick Facts

Property	Description
Active ingredient	Paracetamol (Acetaminophen)
Form	Solid Tablet (Oral)
Pharmacological class	Analgesic and Antipyretic
General Purpose	Relief from pain and fever
Origin	Synthetic (Man-made)

What is Dolo-650 and What is its Main Ingredient?

Dolo-650 is a widely recognized pharmaceutical product whose sole active component is Paracetamol, which is also known internationally as Acetaminophen. This substance, which has the chemical formula C8H9NO2, is a synthetic compound, manufactured chemically rather than being sourced naturally. Dolo-650 is typically supplied in the solid tablet dosage form, intended to be taken orally. The medicine is classified as a single-ingredient product, consisting only of the active drug combined with the necessary inactive base (excipients) required for the stable structure.

Analgesic, Antipyretic: What Type of Medicine is Dolo-650?

Paracetamol is classified as both an Analgesic (pain reliever) and an Antipyretic (fever reducer). This dual classification is reflected in clinical practice, where the medicine is recognized as a standard choice for managing fever and mild to moderate pain. Paracetamol is widely included on essential medicine lists for its confirmed efficacy. This established usage confirms that the drug is globally recognized for its ability to both ease discomfort and regulate body temperature in various situations.

What is the General Purpose of Dolo-650?

The primary purpose of Dolo-650 is to provide general relief from pain and to help lower an elevated body temperature (fever). It achieves this by acting centrally—meaning it affects processes in the brain and spinal cord—which allows it to address symptoms arising from various sources throughout the body. The specific formulation is often used when a standard adult strength of Paracetamol is required, offering a reliable, well-known option for quick access to symptomatic relief.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Dolo - 650?

Possible Side Effects and Safety Information

The safety profile of Dolo-650, which contains Paracetamol (Acetaminophen), is primarily characterized by the risk of severe liver damage (hepatotoxicity), which is associated with exceeding the maximum recommended daily dose or acute overdose, as noted in official regulatory documents. Other adverse effects are classified by frequency and body system.

Adverse Reaction Classification

Official regulatory sources categorize certain adverse reactions based on their observed frequency in clinical use:

Classification	Examples of Documented Reactions
Rare	Increase in hepatic transaminase levels.
Very Rare	Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN); blood disorders such as agranulocytosis and thrombocytopenia.
Not Known	Severe hypersensitivity reactions, including anaphylactic shock and angioedema.

These effects fall primarily under the Hepatobiliary Disorders, Blood and Lymphatic System Disorders, and Skin and Subcutaneous Tissue Disorders system-organ classes.

Safety Considerations and Limitations

Official labeling defines specific safety constraints. The medicine is formally contraindicated in individuals with severe active liver disease. Caution is also required in patients with severe renal impairment, where adjustments to the frequency of administration may be necessary to prevent accumulation. Furthermore, regulatory safety notes explicitly advise against using Paracetamol concurrently with any other product containing the same active ingredient to avoid the acute risk of severe liver damage. Prolonged regular use is also noted to enhance the effect of specific blood thinners (anticoagulants).

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived strictly from official government regulatory documents detailing the acute toxicity profile of the drug's active ingredient (paracetamol/acetaminophen).

Category	Official Regulatory Statements (Label-Derived)
Documented Overdose Manifestations	Initial symptoms may be non-specific, including nausea, vomiting, loss of appetite, and abdominal pain. Severe symptoms such as jaundice, confusion, and coma, indicating liver failure, may be delayed for 12 or more hours after ingestion.
Physiological Systems Affected	The primary critical target is the Liver, potentially resulting in severe hepatic necrosis and acute liver failure. Secondary severe effects involve the Central Nervous System (e.g., seizures, coma) and the Kidneys (e.g., renal failure).
Emergency Management Mandate	Immediate medical help must be sought right away if an overdose is suspected, even if the person appears well and no symptoms are present. Do not wait for symptoms to develop. All cases of suspected overdose must be managed by qualified healthcare professionals.
Antidote Information	A specific antidote, N-acetylcysteine (NAC), is available and is most effective when administered quickly, ideally within eight hours of ingestion. Serum drug concentrations are required to determine the risk and the need for antidote therapy.
Risk Factors	The risk of severe liver damage is increased in individuals with pre-existing liver disease and in those who consume three or more alcoholic drinks daily. Repeated ingestion exceeding the maximum recommended daily dose can also cause serious toxicity.

Taking a dose greater than the recommended amount constitutes an overdose, which regulatory sources state can lead to severe and potentially fatal outcomes. Due to the delayed nature of severe toxicity, the explicit regulatory mandate is to contact emergency services or a poison control center immediately upon suspected ingestion, regardless of the individual's current clinical state.

Therapeutic Uses of Dolo - 650

What Dolo-650 Treats: Main Uses and Benefits

The product is commonly used to help with symptoms related to physical discomfort and systemic temperature elevation (fever). It may be part of symptomatic management, providing support that helps ease the overall symptom burden during acute episodes. The active ingredient is commonly used to help with fever, headaches, and other common aches and pains.

The medication is applied in addressing conditions characterized by periods of heightened symptoms, such as tension headaches, acute toothache, general muscular aches, and the recurrent discomfort of primary dysmenorrhea. It is widely applied in addressing fever and systemic aches associated with illnesses like colds and influenza. Clinical scenarios often include addressing post-procedural discomfort or the pain component of chronic conditions like mild osteoarthritis. This provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic phases.

“It is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.”

This supportive role helps maintain a sense of stability when symptoms are more noticeable, especially for patients who may not tolerate other pain reliever categories.

Quick Fact: Symptomatic Support

Symptom Domain	Use Classification	Patient Benefit
Symptoms related to physical discomfort	Applied when short-term symptomatic assistance is needed	Eases overall discomfort load
Systemic temperature elevation	Relevant in contexts involving heightened systemic burden	Supports general well-being during symptomatic phases

Regulatory References

NIH MedlinePlus overview of OTC Pain Relievers

Eligibility and Restrictions for Use

This section summarizes the official population eligibility and non-eligibility for products containing the active pharmaceutical ingredient, Paracetamol (Acetaminophen), as defined by governmental regulatory documents.

Eligibility and Contraindications

Classification	Populations and Conditions
Use is Contraindicated	Individuals with known hypersensitivity to Paracetamol or any other component in the product. The drug is also contraindicated for patients with severe hepatic impairment or severe active liver disease.
Use Requires Caution	Individuals with impaired renal function or mild hepatic impairment should use the medicine only with professional consultation. Chronic alcohol users, those who are malnourished, or those with a severe infection are also subject to special care and potential dose adjustment.

Age and Physiological Status

Age-Related Eligibility: The product is generally not recommended for children under 10 or 12 years of age on an over-the-counter basis, with specific pediatric instructions required for younger populations.

Pregnancy and Lactation Status: Paracetamol is classified as a medicine that has been used by a large number of pregnant women without a proven increase in the frequency of malformations (Category A in some classifications). It is not contraindicated during breastfeeding, as only very small amounts are excreted into breast milk.

Regulatory documents explicitly state that to avoid the risk of overdose, the product must not be used concurrently with any other medicine containing Paracetamol.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Paracetamol (Acetaminophen), the active ingredient in Dolo-650, is defined by restrictions on co-administration, alterations in systemic exposure, and enhanced toxicity risks, as stated in regulatory documents.

Interaction-Related Restrictions

Co-administration with any other acetaminophen-containing product is strictly restricted (prescription or nonprescription). This is a mandatory regulatory prohibition to prevent exceeding the maximum dose, which carries a risk of severe hepatic injury.

Drug–Drug Interactions

Co-administration with certain medicinal products results in documented pharmacokinetic or pharmacodynamic interactions:

Anticoagulants: Prolonged regular daily use of Paracetamol at higher doses is documented to enhance the anticoagulant effect of Warfarin and other Coumarins, leading to an increased risk of bleeding.
Absorption Modifiers: Metoclopramide and Domperidone officially increase the speed of absorption, while Cholestyramine reduces the absorption of Paracetamol.
Enzyme Inducers: Drugs that induce hepatic enzymes, such as Carbamazepine, Phenytoin, and Rifampicin, are noted to increase the hepatotoxic potential of Paracetamol by altering its metabolic pathway.
Flucloxacillin: Co-administration is associated with an increased risk of High Anion Gap Metabolic Acidosis (HAGMA).

Drug–Substance and Population Interactions

Ethanol (Alcohol): Chronic ingestion of three or more alcoholic drinks per day is an officially listed risk factor associated with increased potential for severe liver damage.
Population-Specific: Patients with underlying conditions such as Chronic Malnutrition or Alcoholism are noted in labeling to have an increased risk of hepatotoxicity.

Mechanism of Action

Paracetamol's mechanism centers primarily on the central nervous system, where it influences biological processes governing the perception of pain (nociception) and the regulation of body temperature (thermoregulation).

Its core action involves the inhibition of prostaglandin synthesis. The key mechanistic target is considered to be the COX-3 enzyme (a splice variant of COX-1), whose activity in the central nervous system is implicated in the prostaglandin-mediated signaling within the hypothalamic thermoregulatory center.

Additionally, the molecule operates via the serotonergic descending inhibitory pathway, demonstrating interaction with 5-HT receptors and components of the nitric oxide pathway to modulate descending pain signals. Crucially, its peripheral activity is limited, resulting in minimal inhibition of COX-1 expressed in the gastric mucosa. This selectivity determines its systemic distribution and site of action.

Dosage and Administration Information

How to Use Dolo-650: Administration Guidelines

The usage of Paracetamol, the active component in Dolo-650, is defined by guidelines regarding route, dosage, and frequency. The medicine is primarily administered via the oral route in tablet form, but a sterile solution is also available for intravenous (IV) infusion in controlled hospital environments.

Standard Dosing and Frequency

Administration is governed by defined limits to prevent unintentional cumulative exposure. For adults, the standard single oral dose ranges from 500 mg to 1,000 mg (1 gram). The minimum time interval required between successive doses is 4 hours.

Regardless of the single dose taken, the established maximum total daily dose from all sources of the active ingredient combined must not exceed 4,000 mg (4 grams) within any 24-hour period. The oral tablet can be taken with or without food; however, consuming it on an empty stomach may accelerate the onset of its administrative effect.

Administration Constraints and Adjustments

Paracetamol is labeled for short-term use to address acute needs, with administration to be discontinued once symptoms have been addressed. The standardized use protocol includes necessary adjustments for certain populations. For example, individuals with renal impairment require an extension of the dosing interval between administrations (e.g., to 6 or 8 hours) to maintain adherence to safe exposure levels. Conversely, no routine adjustment is typically specified based solely on age for older adults.

Feature	Standard Use Principle
Maximum Single Dose	1,000 mg (1 g)
Minimum Dose Interval	4 hours
Max Total Daily Dose	4,000 mg (4 g)

Recent Clinical Evidence

The clinical evaluation for Dolo-650 (Paracetamol or Acetaminophen) is supported by a large body of official research, primarily consisting of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that combine findings from multiple studies. This overview describes the structure of that evidence, focusing on what research has explored and what still remains uncertain, without providing any guidance on usage or clinical decisions.

Evidence for use in Fever Reduction (Antipyresis)

Research has widely examined the drug's use in contexts involving systemic temperature elevation. These studies were conducted during periods of increased symptom activity and used designs like RCTs to explore short-term symptom changes in observed populations of children and adults. Outcomes related to systemic or functional imbalance were monitored, specifically measuring the rate of temperature fall and the time required to achieve a non-febrile state.

Evidence for use in Acute Pain Relief (Analgesia)

A substantial volume of research has examined the drug for outcomes related to physical discomfort associated with acute or disruptive episodes, such as tension headaches, dental pain, and discomfort following surgical procedures. Short-term RCTs and subsequent meta-analyses monitored patient-reported outcomes describing perceived discomfort. The evidence quality varies across studies, and follow-up durations were limited, as most studies track symptom patterns only for the initial acute phase.

Evidence for Chronic or Recurrent Pain

Research has also explored the medicine’s use in conditions involving periods of heightened symptoms, such as the management of mild osteoarthritis pain. Systematic reviews and trials examined how symptoms changed in adults with conditions marked by functional limitations. However, some peer-reviewed analyses suggest that for certain chronic pain conditions, the measured changes during the study period may be small and below the threshold considered clinically important by consensus guidelines.

Research Gaps and Uncertainty

The available research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. Key research gaps include the finding that comparative evidence is lacking when assessing long-term durability of effect. Data show patterns related to heterogeneity, indicating that evidence quality varies across studies when assessing outcomes related to physical discomfort in certain acute settings. Furthermore, there is limited information for long-term outcomes when the medicine is used continuously for chronic conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dolo - 650 (FAQ)

Q: Is Dolo-650 the same as regular paracetamol?

A: Dolo-650 contains the active ingredient Paracetamol (Acetaminophen), which is the same chemical compound found in regular paracetamol. The key difference is the dosage strength: Dolo-650 refers to a 650 mg dose unit, which is higher than the commonly available 500 mg strength.

Q: Why is Dolo-650 called '650'?

A: The number '650' is included in the product name to indicate the precise amount of the active pharmaceutical ingredient present in each tablet. This signifies that the tablet contains 650 milligrams (mg) of Paracetamol (Acetaminophen).

Q: How does Dolo-650 compare to Dolo-500?

A: Dolo-650 contains 650 mg of Paracetamol per tablet, making it a higher single-dose strength than Dolo-500 (500 mg). Both single strengths fall within the official maximum single dose of 1,000 mg. However, taking the 650 mg tablet means users must monitor their total daily intake from all sources to avoid exceeding the official maximum daily dose.

Q: How long does it take for Dolo-650 to start working?

A: Studies on Paracetamol show that it is readily absorbed after administration. Peak plasma concentrations are typically observed between 10 to 60 minutes after administration. Official product information notes that taking the tablet on an empty stomach may accelerate the onset of its effect, but the timeline can vary between individuals.

Q: What is the expected duration of Dolo-650's effect?

A: Official administration guidelines specify that the minimum time interval required between doses is 4 hours. Pharmacokinetic data regarding the medicine's half-life (the time it takes for half the drug to be eliminated from the body) provides an indication of how long the active ingredient remains in the system.

Q: Why do some people experience mild stomach upset after taking Dolo-650?

A: Mild stomach discomfort is not typically listed among the rare or very rare side effects documented in official labeling for Paracetamol. The mechanism of action of Paracetamol results in limited peripheral activity and minimal inhibition of stomach-lining components.

Q: Can people with kidney problems use Dolo-650?

A: Regulatory information indicates that use should be guided by a healthcare professional, as the medicine is generally used with caution in patients with impaired renal (kidney) function. For patients with severe renal impairment, official guidelines may advise extending the time interval between doses to prevent the drug from accumulating in the body.

Q: Is Dolo-650 suitable for elderly individuals?

A: Official administration constraints state that no routine dose adjustment is typically specified solely based on the age of older adults. However, regulatory documents suggest that individuals in the elderly population may require special care due to potential underlying health conditions.

Q: Can teenagers use Dolo-650?

A: The 650 mg strength is typically guided by adult dosing rules for teenagers (those generally over 12 years of age). Administration to teenagers is guided by adult dosing rules and should align with established weight and age criteria for safety.

Q: What kind of pain is Dolo-650 typically used for?

A: As an analgesic (pain reliever), Dolo-650 is officially indicated for the temporary relief of mild to moderate pain. This commonly includes discomfort from issues such as headaches, minor muscle aches, and toothaches, in addition to its use for reducing fever.

Q: Can Dolo-650 be crushed or broken?

A: Solid tablets are typically intended to be swallowed whole unless the official product labeling specifies that they can be split or altered. Altering the dosage form is not standard practice for immediate-release tablets.

Q: Are generic versions of Dolo-650 equally effective?

A: Yes, regulatory agencies like the FDA and EMA require that generic medications containing Paracetamol demonstrate bioequivalence to the originator product. Bioequivalence means the generic drug is required to provide the same rate and extent of absorption as the original.

Q: What is the purpose of the excipients in the Dolo-650 tablet?

A: Excipients are the inactive ingredients included alongside the active drug. Their purpose is to provide the solid tablet with its stable structure, ensuring it is suitable for oral administration and that the active ingredient is released correctly in the body.

Q: Does Dolo-650 affect blood sugar levels?

A: Paracetamol generally does not alter blood glucose levels. However, official information indicates that Paracetamol may interfere with the reading mechanisms of certain continuous glucose monitoring (CGM) devices, which can result in inaccurately high readings on those devices.

Q: What research supports the safety profile of Dolo-650 at its specific strength?

A: The medicine's safety profile is supported by clinical trial data and post-marketing surveillance. This official data informs mandatory regulatory warnings regarding the maximum recommended daily dose and the serious risks associated with hepatic injury if the maximum dose is exceeded.

Q: Does Dolo-650 work differently for different people?

A: Official research data notes patterns related to heterogeneity, which indicates that individual response to the medicine can differ across the population. This variation is a factor in pharmacologic studies.

Q: Is Dolo-650 available over the counter?

A: The active ingredient, Paracetamol, is widely available as a nonprescription (over-the-counter) medicine in many regions. However, local regulatory authorities often place restrictions on the maximum single strength and the overall package size that can be sold without a prescription.

Q: Are there any alternatives to Dolo-650 with the same active ingredient?

A: Yes, Paracetamol (Acetaminophen) is the sole active component used in many different products. It is sold under various trade names and is also readily available in its generic form as an analgesic and antipyretic.

Q: What is the difference between Dolo-650 and other branded paracetamol 650mg tablets?

A: For immediate-release tablets that share the exact same active ingredient and strength (650 mg), all legally marketed versions must meet official bioequivalence standards, meaning they are required to demonstrate comparable efficacy and safety.

Q: Does Dolo-650 have any effect on blood thinning?

A: According to official drug interactions, prolonged, regular daily use of Paracetamol at higher doses is documented to enhance the anticoagulant effect of certain blood thinners, specifically oral anticoagulants like Warfarin. This interaction carries an increased risk of bleeding.

Q: Why do doctors often prescribe Dolo-650 for viral fevers?

A: Dolo-650 is a widely recognized and officially classified antipyretic, meaning it reduces fever. Paracetamol is included on the World Health Organization's list of essential medicines for its established effectiveness in controlling elevated body temperature associated with various causes, including viral infections.

How should Dolo - 650 be stored and disposed of?

Storage Requirements

Paracetamol (Dolo - 650) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with storage temperatures not to exceed 30 C.

The medicine requires protection from both light and moisture and must not be frozen. It must be kept in its original, tightly closed container until use. A mandatory storage requirement is to keep the medicine out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired tablets must follow official pharmaceutical waste guidelines. The preferred method is to use a drug take-back program or mail-back service where available. If no program is available, the product should be mixed with an undesirable substance (e.g., dirt) and placed in a sealed container for household trash, and must not be thrown into wastewater.

Dolo - 650